Welcome to BioSeeker Group!

Analytical Tool - Peptides in Oncology

Additional Information

Published Date Nov 14, 2011
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,100.00

Quick Overview

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development.
Request free sample pages from Analytical Tool - Peptides in Oncology

"Analytical Tool- Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in
    peptide drug development in oncology
  • Information on key industry related
    peptide drug projects in oncology
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

 

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of
    peptide drugs in oncology
  • Identifying emerging peptide cancer products & key areas of pharmaceutical R&D

 

*This software application is a searchable database reflects the most recent advances in the field of peptide drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Peptides in Oncology

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Cancer Immunotherapy
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy. Learn More


Analytical Tool - Angiogenesis in Oncology
The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Leukemia and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Antibodies. Learn More


Antibodies in Oncology Drug Pipeline Update 2011
There are today 294 (248) companies plus partners developing 613 (472) antibody drugs in 1241 (947) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 291 (285) drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 260 (229) different targets. Learn More

Other selected research from the 'Biologicals' category:


Analytical Tool - Antibodies and Peptides in Oncology
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody and peptide cancer R&D and business development. Learn More


Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics
The line between drug delivery and drug substance will continue to become more elusive in the near future as shown in the analysis, as researchers work to improve drug properties... Learn More